Introduction
============

The Chinese Antimicrobial Resistance Surveillance of Nosocomial Infections (CARES) was launched in 2007 to investigate the antimicrobial susceptibility of causative pathogens in nosocomial infections in China. This nationwide surveillance program focuses on nosocomial infections, including bloodstream infections, hospital-acquired pneumonia, and intra-abdominal infections (IAIs), and currently includes 15 tertiary care hospitals.

IAIs are frequently encountered in clinical practice in hospital and healthcare settings. The etiology of these infections, usually polymicrobial in nature, can be diverse and often involves microorganisms derived from the intestinal microbiota.[@b1-idr-11-2311] IAIs are the second most common cause of infectious mortality in intensive care units (ICUs) and commonly result in high mortality and morbidity rates.[@b2-idr-11-2311],[@b3-idr-11-2311] This study aimed to investigate the prevalence, risk factors, and outcomes of nosocomial IAIs in patients admitted to 15 Chinese teaching hospitals involved in the CARES between 2007 and 2016.

Patients and methods
====================

Study centers and patients
--------------------------

A total of 15 study centers were included in the CARES, and this prospective observational study enrolled 2,756 patients with nosocomial IAIs from the CARES program between 2007 and 2016. The criteria for IAI diagnosis were as follows: Presence of organisms cultured from purulent material sampled from the intra-abdominal space during surgical operation or needle aspiration.Presence of abscess or other evidence of IAI observed during surgical operation or histopathologic examination.Presence of at least two of the following signs or symptoms with no other recognized cause: fever (\>38°C), nausea, vomiting, abdominal pain, or jaundice. In addition, at least one of the following criteria is matched: a. Organisms cultured from drainage of a surgically placed drain (such as closed-suction drainage system, open drain, or T-tube drain).b. Organisms observed on Gram's stain of drainage or tissue obtained during surgical operation or needle aspiration.c. Organisms cultured from blood and radiographic evidence of infection (eg, abnormal findings on ultrasound, computed tomography, magnetic resonance imaging, radiolabel scans, or abdominal X-ray radiographs).[@b4-idr-11-2311]

According to the Infectious Diseases Society of America guideline, nosocomial infection includes cases involving patients with positive culture results from a normally sterile site obtained \>48 hours after hospital admission.[@b5-idr-11-2311] This study aimed to investigate the nosocomial IAIs, so patients with positive culture results from intra-abdominal body sites obtained ≤48 hours after admission were excluded. Then all patients enrolled in this study were considered as nosocomial IAIs. Patients with incomplete data were also excluded. All data included were confirmed by chart review.

Bacterial isolates
------------------

All isolates were collected from 15 tertiary care hospitals and cultured from specimens obtained from intra-abdominal body sites (eg, appendix, peritoneum, colon, bile, pelvis, or pancreas).[@b6-idr-11-2311],[@b7-idr-11-2311] Acceptable specimens included tissue, fluid, or deep wound cultures obtained intra-operatively as well as fluid from paracentesis or percutaneous aspiration of abscesses.[@b8-idr-11-2311],[@b9-idr-11-2311] Isolates recovered from blood, urine, and perirectal abscess sources outside the intra-abdominal body sites were excluded.[@b3-idr-11-2311]

Antimicrobial susceptibility testing
------------------------------------

Antimicrobial susceptibility was determined by the agar dilution method and broth microdilution method (only for tigecycline), and the results were interpreted according to the minimum inhibitory concentration (MIC) interpretive breakpoints recommended by the Clinical and Laboratory Standards Institute (CLSI) in 2017.[@b10-idr-11-2311] The tested antimicrobial agents included amikacin, ampicillin, ceftazidime, chloramphenicol, cefotaxime, erythromycin, cefepime, cefoxitin, levofloxacin, moxifloxacin, minocycline, rifampicin, sulfamethoxazole, teicoplanin, vancomycin (National Institute for Food and Drug Control of China, Beijing, China), ciprofloxacin (Bayer AG, Leverkusen, Germany), ceftriaxone (Hoffman-La Roche Ltd., Basel, Switzerland), cefoperazone/sulbactam, piper-acillin/tazobactam, tigecycline (Pfizer, Inc., New York, NY, USA), imipenem (Merck & Co., Inc., Whitehouse Station, NJ, USA), and meropenem (Sumitomo Dainippon Pharma, Osaka, Japan). The tigecycline test was performed according to the Food and Drug Administration standards. The double-disk synergy test was used to determine extended spectrum β-lactamase (ESBL) production among isolates of *Escherichia coli* and *Klebsiella pneumoniae* as recommended by the CLSI.[@b10-idr-11-2311] The reference isolates *E. faecalis* ATCC 29212, *S. aureus* ATCC29213, *E. coli* ATCC 25922 and *P. aeruginosa* ATCC 27853 were used as quality control isolates.

Statistical analyses
--------------------

The chi-squared test or Fisher's exact test was used to compare the categorical variables, and Student's *t*-test was used to compare the continuous variables. To control the effects of confounding variables and identify the independent risk factors associated with death, a stepwise conditional logistic regression analysis was performed.[@b11-idr-11-2311] All variables with a *P*-value \<0.10 in univariate analysis were included in the multivariate logistic model.[@b12-idr-11-2311] OR and 95% CI were calculated. *P*-values \<0.05 were considered statistically significant, and all tests were two-tailed. The WHONET software (version 5.6, <http://www.whonet.org/software.html>) and SPSS (version 22.0) software program (IBM, Armonk, NY, USA) were used for data analyses.

Ethical statement
=================

This study was approved by the research ethics board at Peking University People's Hospital. Informed consent was not needed due to that the medical records and patient information were anonymously reviewed and collected in this observational study.

Results
=======

Baseline data
-------------

A total of 2,756 patients were included in this study: 2,494 patients (90.5%) in the survival group and 262 patients (9.5%) in the nonsurvival group. In the survival group, the median age was 57 years (range, 1--94 years) and 1,509 (60.5%) of them were men. In the nonsurvival group, the median age was 62 years (range, 1--92 years) and 150 (57.3%) of them were men. The 30-day all-cause mortality was 9.5% (262/2756). The main demographic and clinical features of all patients are summarized in [Table 1](#t1-idr-11-2311){ref-type="table"}.

Species distribution of isolates
--------------------------------

A total of 2,913 clinical isolates were collected from intra-abdominal body sites. The species distribution of these isolates is listed in [Table 2](#t2-idr-11-2311){ref-type="table"}. Gram-negative bacteria accounted for 70.8% and Gram-positive bacteria accounted for 29.2% of the isolates. The most common species were *E. coli* (973, 33.4%), *K. pneumoniae* (314, 10.8%), and *Enterococcus faecium* (312, 10.7%), followed by *P. aeruginosa* (230, 7.9%), *Acinetobacter baumannii* (186, 6.4%), *Enterococcus faecalis* (175, 6.0%), *Staphylococcus aureus* (140, 4.8%), and *Enterobacter cloacae* (104, 3.6%).

The species distribution of microorganisms collected from patients hospitalized in the ICU and non-ICU wards is presented in [Table 3](#t3-idr-11-2311){ref-type="table"} (only species with ≥40 isolates are listed). *E. coli*, *A. baumannii*, and *E. cloacae* were more commonly found in ICU patients than in non-ICU patients (*P*\<0.001, *P*\<0.001, and *P*=0.018, respectively).

Risk factors associated with the 30-day mortality
-------------------------------------------------

The results for the stepwise conditional logistic regression analysis of the multiple risk factors associated with death are presented in [Table 4](#t4-idr-11-2311){ref-type="table"}. In the univariate analysis, 30-day mortality was associated with the following 12 factors (*P*\<0.10): age \>60 years (*P*=0.001), pulmonary disease (18.0% vs 12.2%, *P*=0.015), liver disease (19.2% vs 14.5%, *P*=0.059), renal disease (14.2% vs 9.9%, *P*=0.053), central venous catheter (27.5% vs. 21.8%, *P*=0.045), tracheal cannula (20.6% vs 15.6%, *P*=0.053), nasogastric tube (36.0% vs 43.1%, *P*=0.024), infection occurring in ICU (33.7% vs 27.1%, *P*=0.029), prior admission within 3 months (32.1% vs 25.6%, *P*=0.028), antibiotics use before infection (50.5% vs 42.7%, *P*=0.017), recent use of immunosuppressants (14.1% vs 9.2%, *P*=0.022), and multidrug-resistant organisms (21.6% vs 14.9%, *P*=0.009).

Multivariate analysis demonstrated the following independent predictors of death: age \>60 years (OR, 1.109; 95% CI, 1.072--1.325; *P*\<0.001), pulmonary disease (OR, 1.608; 95% CI, 1.023--2.403; *P*=0.027), tracheal cannula (OR, 1.407; 95% CI, 1.081--1.973; *P*=0.035), infection occurring in ICU (OR, 1.338; 95% CI, 1.208--1.911; *P*=0.013), prior admission within 3 months (OR, 1.425; 95% CI, 1.118--1.967; *P*=0.021), antibiotics use before infection (OR, 1.377; 95% CI, 1.048--1.782; *P*=0.009), recent use of immunosuppressants (OR, 1.633; 95% CI, 1.047--2.624; *P*=0.015), and multidrug-resistant organisms (OR, 1.583; 95% CI, 1.098--2.301; *P*=0.002).

Antimicrobial susceptibility of isolates and antimicrobial resistance trends
----------------------------------------------------------------------------

Susceptibility rates, MIC~50~, MIC~90~, and MIC ranges of all isolates causing IAIs between 2007 and 2016 are shown in [Tables S1--S6](https://www.dovepress.com/get_supplementary_file.php?f=182180.pdf). The antimicrobial resistance trends of the main pathogens causing IAIs between 2007 and 2016 are also presented in [Figures S1--S4](https://www.dovepress.com/get_supplementary_file.php?f=182180.pdf).

### Enterobacteriaceae species

In general, tigecycline showed the highest activity (99.8% susceptible) against *Enterobacteriaceae*, followed by imipenem (98.3%), meropenem (97.9%), and amikacin (93.4%). Antimicrobial agents with susceptibility \<50% included cefepime (47.9%), ceftriaxone (33.9%), cefotaxime (32.9%), levofloxacin (30.5%), and ciprofloxacin (29.7%). In addition, there was an increasing trend of carbapenem-resistant *Enterobacteriaceae* species (mainly carbapenem-resistant *E. coli* and carbapenem-resistant *K. pneumoniae*) between 2007 and 2016. The increasing trend of carbapenem-resistant *K. pneumoniae* was more rapid than that of carbapenem-resistant *E. coli*.

### E. coli

A total of 973 isolates were collected, including 491 ESBL-positive isolates and 482 ESBL-negative isolates. For these isolates, meropenem, imipenem, and tigecycline showed the highest activity (all ≥97.8% susceptible) against *E. coli*. However, some antibiotics exhibited very poor potency. Notably, ceftriaxone and cefotaxime were the least active agents, only displaying 0.8% susceptibility against ESBL-positive isolates. In addition, there was a relatively smooth uptrend of ESBL-producing *E. coli* isolates from 47.4% in 2007 to 52.7% in 2016.

### K. pneumonia

A total of 314 isolates were collected, including 77 ESBL-positive isolates and 237 ESBL-negative isolates. Meropenem, imipenem, and tigecycline showed highest activity (all ≥92.0% susceptible) against *K. pneumoniae*. In addition, there was a relatively smooth uptrend of ESBL-producing *K. pneumoniae* isolates between 2007 and 2016 (except in 2011).

### P. aeruginosa and A. baumannii

A total of 230 *P*. *aeruginosa* isolates and 186 *A. baumannii* isolates were tested. Almost all the isolates showed high- level resistance to diverse antimicrobial agents. However, only amikacin exhibited good activity (83.4% susceptible) against *P. aeruginosa*.

With regard to *A. baumannii* isolates, tigecycline exhibited the highest activity (84.4% susceptible) among the tested antimicrobial agents. *A. baumannii* was alarmingly resistant to diverse classes of antibiotics including third-generation cephalosporins, fluoroquinolones, aminoglycosides, and carbapenems.

Both *P. aeruginosa* and *A. baumannii* showed the same trend of an initial increase followed by a decrease in resistance to carbapenems. Nonetheless, a high resistance to carbapenems was a big threat with both the organisms.

### S. aureus

A total of 140 *S*. *aureus* isolates were collected, including 89 methicillin-susceptible *S. aureus* (MSSA) isolates (63.6%) and 51 methicillin-resistant *S. aureus* (MRSA) isolates (36.4%). All these isolates were susceptible to teicoplanin and vancomycin. In addition, all MSSA isolates were susceptible to minocycline. In contrast, fluoroquinolones (ciprofloxacin, levofloxacin, and moxifloxacin) exhibited very poor activity against MRSA isolates. Erythromycin exhibited poor activity against both MRSA (13.8% susceptible) and MSSA (37.2% susceptible) isolates. The MRSA isolates showed an increasing trend from 2011 to 2016.

### E. faecalis and E. faecium

A total of 175 *E. faecalis* and 312 *E. faecium* isolates were collected. All the isolates were susceptible to teicoplanin and vancomycin (≥97.4% susceptible). Overall, *E. faecium* isolates had a high resistance (84.0% resistant) to ampicillin, whereas *E. faecalis* isolates were much more susceptible to ampicillin (93.5% susceptible). Only 1.9% of *E. faecium* isolates showed resistance to vancomycin with a decreasing trend in resistance between 2007 and 2016.

Discussion
==========

In this study, we investigated the risk factors for nosocomial IAIs and the outcomes of these infections. We found that age \>60 years, pulmonary disease, tracheal cannula, infection occurring in ICU, prior admission within 3 months, antibiotics use before infection, recent use of immunosuppressants, and multidrug-resistant organisms were independent predic tors of patient survival. Compared to other representative surveillance programs which monitor the epidemiology and trends in antibiotic resistance of intra-abdominal pathogens to currently used therapies, such as the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, this study collected the demographic and clinical data of the patients in detail and analyzed the risk factors and clinical outcomes of nosocomial IAIs in China. The data and results of this study may be helpful to the IAI treatment in clinic.

A total of 2,913 isolates were collected from 15 tertiary care teaching hospitals involved in the CARES between 2007 and 2016. We analyzed the updated epidemiology and antimicrobial susceptibility of the causative pathogens. The epidemiological data from our study highlights the diversity of intra-abdominal pathogens, as many different species causing IAIs were isolated. Of these, the most common species were *E. coli* (33.4%), *K. pneumoniae* (10.8%), and *E. faecium* (10.7%). Not surprisingly, *Enterobacteriaceae* isolates were the predominant species causing IAIs, accounting for at least 50% of all isolated pathogens.

Our study using data from the CARES program revealed several important findings. First, the combinations of cephalosporins, fluoroquinolones, and β-lactam/β-lactamase inhibitors tested in the CARES exhibited diminished susceptibility against the collected isolates over the study period. Second, the nonfermentative Gram-negative bacilli were alarmingly resistant to diverse classes of antimicrobial agents. The susceptibilities of *A. baumannii* isolates to carbapenems, third- or fourth-generation cephalosporins, fluoroquinolones, and aminoglycosides were less than \~30%, which presents a key problem for empirical therapeutic choice. Although *A. baumannii* was not a major pathogen for IAIs, the trends of its resistance, especially, to carbapenems should be monitored.[@b13-idr-11-2311] Third, amikacin, tigecycline, and carbapenems including imipenem and meropenem were consistently potent against *Enterobacteriaceae* isolates throughout the study period. Thus, tigecycline monotherapy, carbapenem monotherapy, or amikacin-based combination therapy could provide the strongest activity against *Enterobacteriaceae* causing IAIs.[@b8-idr-11-2311] Fourth, the overall increase in the isolation of Gram-positive pathogens was accompanied by an increase in the multidrug-resistant phenotypes, making it difficult to choose the appropriate therapy for IAIs.

In our study, ESBL-producing isolates showed high-level resistance to diverse antimicrobial agents. A high prevalence of ESBL-producing isolates in China has been reported in several studies, and the continually diminishing susceptibility to many antimicrobial agents is alarming.[@b6-idr-11-2311],[@b14-idr-11-2311] The SMART study, which monitored the resistance of Gram-negative pathogens causing IAIs, showed that 43.9% of *E. coli* and 30.4% of *K. pneumoniae* isolates were ESBL producers.[@b3-idr-11-2311] These ESBL-producing strains exhibited resistance to more antibiotics than non-ESBL-producing strains. Our current study showed that carbapenems and amikacin are the most active antibiotics, which was consistent with our antimicrobial susceptibility results. So far, the recommended antibiotics for the treatment of serious infections caused by ESBL-producing bacteria are carbapenems, particularly for patients with severe sepsis.[@b15-idr-11-2311] A previous study showed that the adequacy of initial antibiotic therapy for serious ESBL-infection was associated with mortality.[@b16-idr-11-2311]

A steady decrease in the susceptibility to most non-carbapenem antimicrobial agents has been observed over time; however, the carbapenem consumption has increased and maybe the reason for the increasing carbapenem resistance reported among *Enterobacteriaceae* species.[@b17-idr-11-2311] Despite increased consumption of carbapenems and the emergence of varieties of carbapenem resistant mechanisms, susceptibility of *Enterobacteriaceae* species to carbapenems was consistently high in our study.

Infections caused by resistant microorganisms increase the risk of mortality, especially because the initial empiric therapy may be inadequate.[@b1-idr-11-2311] Due to the dissimilarity in the nature of the IAI pathogens, appropriate antibiotics for IAIs were studied, leading to differences in antibiotic treatment. Two publications were recommended as guidelines for empirical antibiotic treatment for IAIs.[@b18-idr-11-2311],[@b19-idr-11-2311] To select adequate therapy for IAIs in clinical practice, updated data on the local resistance epidemiology of these pathogens should be available;[@b1-idr-11-2311] therefore, surveillance studies are necessary. Many epidemiological surveillance programs and studies worldwide, such as the SMART, China antimicrobial Surveillance Network (<http://www.chinets.com>), and CARES, have provided important information on the pathogens involved in many infections and ongoing resistance to the main classes of antibiotics used in clinical practice. Surveillance studies are key in not only identifying specific pathogens associated with IAIs but also assessing resistance rates and trends in resistance for antimicrobials commonly used to treat IAIs. The combination of resistance rates, trends in resistance over time, and trends in mechanisms of resistance will help physicians, pharmacists, and clinical microbiologists understand the evolution and spread of pathogens.[@b20-idr-11-2311]

Despite our important findings, the main problem of the present study is that it is observational in nature, which might result in limitations that preclude accurate comparisons, and thus unknown risk factors might have been unequally distributed between groups.

Conclusion
==========

Antibiotic resistance among IAI-causing species is a serious threat in China, and close monitoring of antibiotic resistance among pathogens associated with IAIs is crucial for guiding measures to prevent further emergence of resistance and to provide clinicians with the necessary information to appropriately select empirical therapy. Up-to-date national, regional, and global microbial surveillance is needed to provide updated information for the optimal therapy of IAIs.
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###### 

Demographic and clinical features of the 2,756 patients with IAIs in the study

                                          Survival group (n=2494, 90.5%)   Nonsurvival group (n=262, 9.5%[a](#tfn1-idr-11-2311){ref-type="table-fn"})   *P*-value          
  --------------------------------------- -------------------------------- ---------------------------------------------------------------------------- ----------- ------ -------
                                                                                                                                                                           
  **Demographics**                                                                                                                                                         
   Age, years, median (range)             57(1--94)                        --                                                                           62(1--92)   --     --
   Gender, male                           1,509                            60.5                                                                         150         57.3   0.307
  **Comorbidities**                                                                                                                                                        
   Pulmonary disease                      450                              18.0                                                                         32          12.2   0.015
   Liver disease                          479                              19.2                                                                         38          14.5   0.059
   Renal disease                          353                              14.2                                                                         26          9.9    0.053
   Cardiovascular disease                 382                              15.3                                                                         40          15.3   0.997
   Neurological disease                   90                               3.6                                                                          15          5.7    0.105
   Cancer                                 423                              17.0                                                                         55          21.0   0.107
   Diabetes mellitus                      292                              11.7                                                                         37          14.1   0.256
   Agranulocytosis                        22                               0.9                                                                          5           1.9    0.144
  **Invasive procedures**                                                                                                                                                  
   Splenectomy                            27                               1.1                                                                          5           1.9    0.259
   Tracheotomy                            208                              8.3                                                                          20          7.6    0.712
   Arterial catheter                      382                              15.3                                                                         37          14.1   0.619
   Central venous catheter                685                              27.5                                                                         57          21.8   0.045
   Tracheal cannula                       514                              20.6                                                                         41          15.6   0.053
   Foley catheter                         1,075                            43.1                                                                         121         46.2   0.340
   Nasogastric tube                       898                              36.0                                                                         113         43.1   0.024
  **Other important clinical features**                                                                                                                                    
   Infection occurred in ICU wards        841                              33.7                                                                         71          27.1   0.029
   Use of multiple antimicrobial agents   534                              21.4                                                                         66          25.2   0.173
   Surgical treatment                     1,372                            55.0                                                                         143         54.6   0.893
  **Past medical history**                                                                                                                                                 
   Drinking history                       404                              16.2                                                                         41          15.6   0.831
   Smoking history                        464                              18.6                                                                         54          20.6   0.427
   Prior admission within 3 months        801                              32.1                                                                         67          25.6   0.028
   Antibiotic use before infection        1,259                            50.5                                                                         112         42.7   0.017
   Recent surgery                         1,200                            48.1                                                                         135         51.5   0.294
   Recent use of corticosteroids          481                              19.3                                                                         44          16.8   0.330
   Recent use of immunosuppressant        351                              14.1                                                                         24          9.2    0.022
  **Bacteria isolated from patients**                                                                                                                                      
   Gram-negative bacteria                 1,773                            71.1                                                                         182         69.5   0.579
   Multidrug-resistant organisms          538                              21.6                                                                         39          14.9   0.009
  **Sources of the IAI**                                                                                                                                                   
   Peritoneum and peritoneal cavity       496                              19.9                                                                         59          22.5   0.314
   Abdominal and pelvic organs            1905                             76.4                                                                         189         72.2   0.130

**Note:**

9.5% is 30-day all-cause mortality.

**Abbreviations:** IAI, intra-abdominal infection; ICU, intensive care unit.

###### 

Species distribution of the main pathogens in all IAI cases

  Species                         N           \%
  ------------------------------- ----------- ----------
                                              
  **Gram-negative bacteria**      **2,063**   **70.8**
                                              
   Enterobacteriaceae             1,559       53.5
    E. coli                       973         33.4
    K. pneumoniae                 314         10.8
    E. cloacae                    104         3.6
    Others                        168         5.8
   Nonfermentative bacteria       454         15.6
    P. aeruginosa                 230         7.9
    A. baumannii                  186         6.4
    Others                        38          1.3
   Other Gram-negative bacteria   50          1.7
  **Gram-positive bacteria**      **850**     **29.2**
   Enterococcus                   539         18.5
    E. faecalis                   175         6.0
    E. faecium                    312         10.7
    Others                        52          1.8
   Staphylococcus                 271         9.3
    S. aureus                     140         4.8
    Staphylococcus haemolyticus   41          1.4
    Staphylococcus epidermidis    65          2.2
    Others                        25          0.9
   Other Gram-positive bacteria   40          1.4

**Abbreviation:** IAI, intra-abdominal infection.

###### 

Species distribution[a](#tfn4-idr-11-2311){ref-type="table-fn"} of microorganisms collected from IAI patients hospitalized in ICU and non-ICU

  Species             Total   ICU    Non-ICU   *P*-value                 
  ------------------- ------- ------ --------- ----------- ------ ------ ---------
                                                                         
  Total               2,540   100    599       23.6        1941   76.4   
  *E. coli*           973     38.3   186       19.1        787    80.9   \<0.001
  *K. pneumoniae*     314     12.4   76        24.2        238    75.8   0.837
  *E. faecium*        312     12.3   84        26.9        228    73.1   0.158
  *P. aeruginosa*     230     9.1    47        20.4        183    79.6   0.272
  *A. baumannii*      186     7.3    81        43.5        105    56.5   \<0.001
  *E. faecalis*       175     6.9    49        28.0        126    72.0   0.182
  *S. aureus*         140     5.5    34        24.3        106    75.7   0.921
  *E. cloacae*        104     4.1    14        13.5        90     86.5   0.018
  *S. epidermidis*    65      2.6    18        27.7        47     72.3   0.520
  *S. haemolyticus*   41      1.5    10        24.4        31     75.6   0.950

**Note:**

Only species with ≥40 isolates are listed in the table.

**Abbreviations:** IAI, intra-abdominal infection; ICU, intensive care unit.

###### 

Univariate and multivariate analyses of the risk factors associated with 30-day all-cause mortality

                                          Univariate analysis   Multivariate analysis                                  
  --------------------------------------- --------------------- ----------------------- ------- ------- -------------- ---------
                                                                                                                       
  **Demographics**                                                                                                     
   Age \>60 years                         1.034                 1.026--1.052            0.001   1.109   1.072--1.325   \<0.001
   Gender, male                           1.144                 0.883--1.479            0.307                          
  **Comorbidities**                                                                                                    
   Pulmonary disease                      1.582                 1.089--2.354            0.015   1.608   1.023--2.403   0.027
   Liver disease                          1.401                 0.988--2.027            0.059   1.497   0.997--2.019   0.053
   Renal disease                          1.496                 0.996--2.319            0.053   1.476   0.991--2.239   0.051
   Cardiovascular disease                 1.004                 0.710--1.445            0.997                          
   Neurological disease                   0.617                 0.359--1.117            0.105                          
   Cancer                                 0.769                 0.564--1.061            0.107                          
   Diabetes mellitus                      0.807                 0.562--1.179            0.256                          
   Agranulocytosis                        0.458                 0.180--1.367            0.144                          
  **Invasive procedures**                                                                                              
   Splenectomy                            0.563                 0.227--1.657            0.259                          
   Tracheotomy                            1.101                 0.694--1.818            0.712                          
   Arterial catheter                      1.100                 0.770--1.602            0.619                          
   Central venous catheter                1.362                 1.007--1.862            0.045   1.307   0.976--1.834   0.064
   Tracheal cannula                       1.399                 0.996--2.000            0.053   1.407   1.081--1.973   0.035
   Foley catheter                         0.883                 0.684--1.141            0.340                          
   Nasogastric tube                       0.742                 0.574--0.962            0.024   0.796   0.652--1.157   0.069
  **Other important clinical features**                                                                                
   Infection occurring in ICU             1.369                 1.033--1.828            0.029   1.388   1.208--1.911   0.013
   Use of multiple antimicrobial agents   0.813                 0.608--1.098            0.173                          
   Surgical treatment                     1.018                 0.787--1.314            0.893                          
  **Past medical history**                                                                                             
   Drinking history                       1.042                 0.740--1.493            0.831                          
   Smoking history                        0.881                 0.645--1.216            0.427                          
   Prior admission within 3 months        1.377                 1.034--1.849            0.028   1.425   1.118--1.967   0.021
   Antibiotics use before infection       1.365                 1.056--1.768            0.017   1.377   1.048--1.782   0.009
   Recent surgery                         0.872                 0.849--1.677            0.294                          
   Recent use of corticosteroids          1.184                 0.639--1.523            0.330                          
   Recent use of immunosuppressants       1.624                 1.067--2.558            0.022   1.633   1.047--2.624   0.015
  **Bacteria isolated from patients**                                                                                  
   Gram-negative bacteria                 1.081                 0.817--1.422            0.579                          
   Multidrug-resistant organisms          1.572                 1.113--2.263            0.009   1.583   1.098--2.301   0.002
  **Sources of the IAI**                                                                                               
   Peritoneum and peritoneal cavity       0.854                 0.632--1.167            0.314                          
   Abdominal and pelvic organs            1.249                 0.935--1.657            0.130                          

**Abbreviations:** IAI, intra-abdominal infection; ICU, intensive care unit.
